Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Discontinued
Reference number: GID-TA10926
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Venetoclax with dexamethasone within its marketing authorisation for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in mid-July 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2023.